News & events

Press releases

Press releases

RSS Feed
23 November 2021, Sophia-Antipolis, France

Median Technologies announces new outstanding performance for its iBiopsy® Lung Cancer Screening CADx with a focus on stage 1 lung cancer characterization

Median Technologies (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules. New results specifically focus on the characterization of stage 1 lung cancer nodules, using Median’s proprietary iBiopsy® deep learning algorithm on low-dose chest computed tomography (LDCT).

Read more
16 September 2021, Sophia Antipolis, France

Median Technologies has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world, and selected to implement their clinical trial imaging strategy on some key oncology indications

This is the result of the renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company. The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years. This partnership will contribute to sustain Median’s future bookings and revenues growth.

Read more

Filter news articles by year

News and events

Email alerts